Our objective was to determine if b 1 -adrenergic receptor (b 1 -AR) and b 2 -AR gene polymorphisms influence heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) response to dobutamine during dobutamine stress echocardiography (DSE). Patients (n ¼ 163) undergoing clinically indicated DSE were enrolled. Dobutamine doses were titrated from 5 to 40 mg kg À1 min À1 at 3 min intervals and HR, SBP and DBP were measured. Genotypes were determined for b 1 -AR Ser49Gly, b 1 -AR Arg389-Gly, b 2 -AR Arg16Gly and b 2 -AR Gln27Glu polymorphisms by polymerase chain reaction-restriction fragment length polymorphism analysis, pyrosequencing and single primer extension methods. b 2 -AR Glu27 homozygotes had a greater HR response at the highest dobutamine dose than Gln27 carriers (P ¼ 0.002). b 2 -AR Gly16 homozygotes had a lower HR response during 5-30 mg kg À1 min À1 of the dobutamine infusion protocol compared to Arg16 carriers (P ¼ 0.03). Differences in SBP by b 2 -AR codon 16 genotype and DBP by b 1 -AR codon 389 genotype were found at baseline and were maintained throughout DSE (P ¼ 0.06 and 0.02, respectively). However, the magnitude of SBP and DBP response to dobutamine did not differ significantly by b 2 -AR codon 16 or b 1 -AR codon 389 genotypes, respectively. These data suggest that the four selected b 1 -and b 2 -AR polymorphisms do not substantially influence the magnitude of hemodynamic response to dobutamine during DSE.
Introduction
Common polymorphisms exist in the genes that encode the b 1 -and b 2 -adrenergic receptors (b 1 -and b 2 -AR). These include a serine to glycine at b 1 -AR codon 49 (Ser49Gly), an arginine to glycine at b 1 -AR codon 389 (Arg389Gly), an arginine to glycine at b 2 -AR codon 16 (Arg16Gly) and a glutamine to glutamic acid at b 2 -AR codon 27 (Gln27Glu). In vitro studies have provided evidence for their functional basis, [1] [2] [3] and these polymorphisms have been implicated in differential response to b 1 -and b 2 -AR antagonists and agonists in numerous studies. Specifically, studies have shown that b 1 -AR genotype is a significant predictor of blood pressure and ejection fraction responses to b-blockers, [4] [5] [6] [7] [8] and responses to b 2 agonists have been associated with b 2 -AR polymorphisms.
Dobutamine is a potent synthetic intravenous inotrope that is principally an agonist at b 1 -AR with mild stimulatory effects at b 2 -AR and a 1 -AR. A recent study in healthy volunteers pretreated with atropine showed that b 1 -AR codon 389 genotype was associated with greater contractile and systolic blood pressure (SBP) response to dobutamine. 11 This interesting study provided insight into the potential role of b 1 -AR polymorphisms in response to a commonly used b-agonist. However, since this study was conducted in the presence of parasympathetic nervous system blockade, the relationship between response and genotype in the presence of an intact parasympathetic nervous system, as would be the norm in the clinical setting, is unknown. Additionally, the study did not examine the effects of b 2 -AR polymorphisms on response to dobutamine.
Due to dobutamine's positive inotropic and chronotropic effects, dobutamine stress echocardiography (DSE) has become a popular method for the detection of coronary artery disease in patients unable to undergo standard exercise stress testing. 12, 13 Some patients experience a rapid heart rate (HR) response following dobutamine administration, while others require maximum dobutamine infusion doses or addition of atropine to reach their target HR. 14 In addition, some patients experience marked hypertension or hypotension during the DSE protocol that limits the ability to complete the test and achieve target HR. [15] [16] [17] Given the previous data, we hypothesized that b 1 -and b 2 -AR polymorphisms would be associated with HR, SBP and diastolic blood pressure (DBP) responses to dobutamine in the clinical setting, and might help explain some of the commonly observed interpatient variability in hemodynamic responses to dobutamine during DSE testing. Thus, we prospectively tested this hypothesis in patients undergoing clinically indicated DSE, but prior to administration of atropine.
Results

Study population
The study consisted of 163 patients (79 men, 84 women; 132 Caucasians of which 7 indicated Hispanic ethnicity; 26 Blacks; 3 Asians; 1 Pacific Islander and 1 patient who classified their race as other). Allele frequencies and genotype distributions are shown in Table 1 . b 1 and b 2 receptor genotypes were in Hardy-Weinburg equilibrium. Baseline demographics by genotype are shown in Table 2 . The mean age of the study population was 56 ± 11 years (range 32-83 years). The most common concomitant disease state in the population was hypertension (n ¼ 106; 65%). The number of patients with a history of hypertension did not differ significantly between any of the b-AR genotype groups. Body mass index differed significantly between b 2 -AR codon 27 Gln/Gln and Gln/Glu genotype groups (P ¼ 0.005). Overall, 44% of the patients in this study required atropine after the 40 mg kg À1 min À1 dobutamine dose in order to reach their target HR. There were no significant differences by b 1 -or b 2 -AR genotype groups in patients who required vs did not require atropine administration (data not shown).
Resting hemodynamics
Resting HR, SBP and DBP were compared by genotype (Table 3 ; entire study cohort). Resting SBP and DBP differed significantly by b 1 -AR codon 389 genotype and b 2 -AR codon 16 genotype. The rate of antihypertensive medication use did not differ between b 1 -AR codon 389 or b 2 -AR codon 16 genotype groups. Resting SBP and DBP were significantly higher in b 1 -AR Arg389 homozygotes as compared to Gly389 carriers in the entire study cohort (P ¼ 0.012 and 0.025, respectively; Table 3 ). Similarly, resting SBP and DBP were significantly higher in b 2 -AR Gly16 carriers as compared to Arg16 homozygotes (P ¼ 0.027 and 0.019, respectively; Table 3 ). When the Caucasian patients were analyzed alone, resting SBP and DBP were significantly higher in b 1 -AR Arg389 homozygotes as compared to Gly389 carriers (systolic 152 ± 24 vs 135 ± 28 mm Hg, P ¼ 0.001; diastolic 81±12 vs 75±14 mm Hg, P ¼ 0.01). In Caucasians, resting SBP was significantly higher in b 2 -AR Gly16 homozygotes compared to Arg16 homozygotes (148 ± 26 vs 132 ± 25; P ¼ 0.027), and Gly16 homozygotes compared to heterozygotes (147±27 vs 132±25; P ¼ 0.028). Resting DBP was also higher in b 2 -AR Gly16 homozygotes compared to Arg16 homozygotes (80 ± 13 vs 73 ± 14; P ¼ 0.07), and higher in heterozygotes compared to Arg16 homozygotes (80±14 vs 73 ± 14; P ¼ 0.04). b 1 -AR codon 49 and b 2 -AR codon 27 genotypes did not significantly influence resting SBP or DBP in the entire study cohort, nor when analyzed in the Caucasian group alone. Similarly, resting HR did not differ Heart rate response during DSE There was a significant difference in the pattern of HR response to dobutamine over time between b 2 -AR codon 27 genotypes (P ¼ 0.002, all patients, Figure 1a ; P ¼ 0.002, Caucasians only, Figure 1b ). During the early stages of the dobutamine infusion (that is, 0-30 mg kg À1 min
À1
), the mean HR of b 2 -AR Glu27 homozygotes was similar to those with the Gln/Glu genotype. However, in the later stages of the infusion protocol (that is, 40 mg kg À1 min À1 ), Glu27 homozygotes demonstrated a greater HR response to dobutamine compared to those who carried a Gln27 allele. There was also a significant difference in the pattern of HR response to dobutamine over time between b 2 -AR codon 16 genotypes (P ¼ 0.03, all patients, Figure 2a ; P ¼ 0.03, Caucasians only, Figure 2b ). Throughout the majority of the dobutamine infusion protocol (that is, 5-30 mg kg À1 min À1 ), b 2 -AR Gly16 homozygotes had a lower HR response compared to Arg16 carriers. It is unlikely that these differences were due to baseline differences by genotype as there were no significant differences in baseline HR between b 2 -AR codon 27 genotype groups or codon 16 genotype groups. The pattern of dose-HR response did not differ significantly by b 1 -AR codon 389 or codon 49 genotype in the entire study cohort, 
0.027 0.019 NS P-value Arg/Arg vs Arg/Gly 0.008 0.006 -P-value Arg/Arg vs Gly/Gly 0.024 0.018 -P-value Arg/Gly vs Gly/Gly NS NS - Systolic blood pressure response during DSE Systolic blood pressure was higher in b 2 -AR Gly16 carriers compared to Arg16 homozygotes throughout the DSE testing period (P ¼ 0.06, all patients, Figure 3a ; P ¼ 0.06, Caucasians only, Figure 3b) , although this appears to be due to higher SBP at baseline in this group. The magnitude of SBP response to dobutamine was similar across b 2 -AR codon 16 genotype groups, thus maintaining the differences observed at baseline. Of more clinical relevance is that of 16 patients who demonstrated a marked hypertensive response to dobutamine, defined as SBP X200 mm Hg, 15 (94%) of these patients carried a Gly16 allele. The baseline differences in SBP that were noted by b 1 -AR codon 389 genotype were maintained during the dobutamine infusion, although these differences did not reach statistical significance (P ¼ 0.08, all patients, data not shown; P ¼ 0.12, Caucasians only, data not shown). There were no significant differences in SBP response to dobutamine for the b 1 -AR codon 49 or b 2 -AR codon 27 polymorphisms in the entire study cohort, nor when analyzed by Caucasians alone (data not shown).
Diastolic blood pressure response during DSE Throughout DSE testing, DBP was significantly higher in b 1 -AR Arg389 homozygotes, as compared to Gly389 carriers (P ¼ 0.02, all patients, Figure 4a ; P ¼ 0.02, Caucasians only, Figure 4b ). This was not due to genotype differences in the magnitude of DBP change with increasing dobutamine doses, but was rather due to baseline differences in DBP that were maintained throughout DSE testing. There were no significant differences in DBP response for the b 1 -AR codon 49, b 2 -AR codon 16 or b 2 -AR codon 27 polymorphisms across the DSE testing period in the entire study b-Receptor polymorphisms and response to dobutamine CL Aquilante et al cohort, nor when analyzed in the Caucasians alone (data not shown). Dobutamine-stimulated hemodynamic data were also analyzed according to the number of copies of the b 1 -and b 2 -AR haplotypes. Like resting hemodynamics, haplotype analysis was not any more informative of dobutamine response hemodynamics than single SNP analysis.
Discussion
Interpatient variability exists in the HR and blood pressure response to dobutamine. The purpose of this study was to determine whether interpatient variability in hemodynamic response was associated with four selected polymorphisms in the b 1 -and b 2 -AR genes. Our data suggest that the four selected b 1 -and b 2 -AR polymorphisms do not contribute substantially to interpatient variability in the magnitude of HR, SBP or DBP response to dobutamine during DSE testing. We did find that b 2 -AR Glu27 homozygotes had a greater HR response to dobutamine, but this was only noted at the highest dose, which many patients never reach in the clinical setting. Along the same lines, b 2 -AR Gly16 homozygotes had lower HRs during the middle stages of the dobutamine infusion protocol (that is, 5-30 mg kg À1 min À1 ) compared to Arg16 carriers. However, these differences were no longer evident at the maximum dobutamine dose (that is, 40 mg kg À1 min À1 ), and did not result in an increased need for atropine to reach target HR. During DSE testing, we also found that SBP and DBP were higher in b 2 -AR Gly16 carriers and b 1 -AR Arg389 homozygotes, respectively. These differences were not due to differences in the magnitude of response to dobutamine, but rather maintenance of baseline blood pressure differences by genotype. However, this may represent the finding of greatest clinical relevance since 94% of those with a marked hypertensive response to dobutamine (that is, attainment of a SBP X200 mm Hg) were carriers of a b 2 -AR Gly16 allele.
It is of interest to note that our findings regarding b 1 -AR codon 389 genotype and SBP response to dobutamine are in contrast to another study that evaluated dobutamine response in the presence of parasympathetic blockade (that is, atropine) in healthy volunteers. 11 In this previous study, b 1 -AR Arg389 homozygotes had a greater increase in SBP response to dobutamine than Gly389 carriers. In contrast, we found that although SBP was higher throughout DSE testing in b 1 -AR Arg389 homozygotes compared to Gly389 carriers, this was likely due to baseline blood pressure differences by genotype that were maintained throughout testing. Moreover, the magnitude of SBP response in our study did not differ between genotype groups. The difference in findings between the two studies might be attributable to differences in the populations evaluated (that is, healthy subjects vs patients undergoing clinically indicated DSE testing). However, it is more likely that the parasympathetic response that occurred in our study attenuates the differences in dobutamine response by genotypes that were noted in the healthy volunteer study, where the parasympathetic system was blocked by atropine.
The effect of these polymorphisms on resting HR and HR response to dobutamine is also of interest. When the in vitro functional consequences of the b 1 -AR codon 389 polymorphism were first described, 1 there was a strong expectation that this genotype would influence HR and HR response to agonists and antagonists. However, this was not the case in our study, as b 1 -AR codon 389 genotype did not influence dobutamine-stimulated HR response or resting HR in our population. These findings are concordant with the study by La Rosee et al., 11 where b 1 -AR codon 389 genotype had no effect on HR response to dobutamine during DSE testing in healthy volunteers pretreated with atropine. In addition, our findings are largely consistent with the literature in that b 1 -AR codon 389 genotype does not appear to influence HR response to b-receptor agonists, antagonists or exercise, nor does it appear to affect resting HR. [4] [5] [6] [18] [19] [20] [21] Taken together, these data in myriad patient populations suggest that while the functional effects of the b 1 -AR codon 389 polymorphism have been documented in numerous settings, it seems now it may be clearly concluded that this polymorphism does not affect HR, or its responses to agonists, antagonists or exercise.
The limitations of our study deserve to be addressed. In order to determine if b 1 -and b 2 -AR polymorphisms influenced interindividual variability in hemodynamic response to dobutamine during DSE, we studied hemodynamic response to dobutamine in a group of patients undergoing clinically indicated DSE. Despite the heterogeneous nature of our patient population, our baseline demographics suggest that the population was well balanced with respect to confounders such as age, sex, history of hypertension and smoking status. Due to the known racial differences in b 1 -and b 2 -AR polymorphism allele frequencies, race was included as a covariate in statistical analyses of the hemodynamic response data. In addition, we analyzed the hemodynamic response data in Caucasians alone. The hemodynamic response data in Caucasians were consistent with those found in the entire study cohort. As such, it does not appear that population stratification or racial differences in allele frequencies confounded our analysis. Furthermore, because our study was designed to mirror dobutamine use in clinical practice, we were unable to delineate the effects of b 1 -and b 2 -AR polymorphisms on the pure adrenergic effects of dobutamine. However, our study does provide relevant information on differential hemodynamic responses to dobutamine using a standard clinical protocol in a population of patients that is routinely administered the drug.
In summary, our study suggests that the two selected b 2 -AR polymorphisms contribute little to interpatient variability in HR response to dobutamine in the clinical setting, and thus would probably hold little, if any, clinical value in predicting dobutamine HR response. In terms of blood pressure response, our findings revealed that b 2 -AR codon 16 genotype influenced baseline blood pressure and may be an indicator of patients who are predisposed to having a marked hypertensive response to dobutamine. Additional studies exploring this association are warranted. The differences in findings between our study and another that studied dobutamine response during parasympathetic blockade highlight the tight interplay and regulation of hemodynamics by the sympathetic and parasympathetic nervous systems, and suggest that one system may help offset the consequences of genetic polymorphisms in the other system.
Materials and methods
Study design
This study was conducted in patients X18 years of age who were undergoing clinically indicated DSE at Shands Hospital at the University of Florida. The study was approved by the University of Florida Institutional Review Board and all subjects gave written informed consent. After obtaining consent, a brief patient interview was performed by the study investigators and the indication for DSE, concomitant medications and concomitant disease states were recorded. Patients were excluded from the study if they had taken a b-blocker within four half-lives before the DSE test. Indications for DSE included chest pain evaluation, preoperative medical clearance or pretransplant evaluation (kidney, liver, lung or heart). At the time of DSE testing, a 5 ml blood sample or 15 ml mouthwash sample was obtained from each patient for genetic analyses.
DSE was performed by a trained nurse using a standard hospital protocol that has been previously described. 16 Briefly, dobutamine was administered intravenously at a starting dose rate of 5 mg kg À1 min À1 . The dobutamine dose rate was titrated at 3-min intervals to 10, 20, 30 and 40 mg kg À1 min À1 . The infusion was terminated when the patient reached target HR, calculated as 85% of the agepredicted maximum HR (defined as 220 minus age in years). If target HR was not reached after the 40 mg kg À1 min À1 dose, 0.25-1 mg atropine was administered intravenously. The dobutamine infusion was also terminated if the patient developed myocardial ischemia, hemodynamic compromise or intolerable symptoms. HR (based on 12-lead electrocardiogram) and blood pressure (using a ProPak 104EL; Protocol Systems Inc., Beaverton, OR, USA) were measured at baseline (after a rest period), at the start of the dobutamine infusion period and at the end of each 3-min b-Receptor polymorphisms and response to dobutamine dobutamine infusion increment. Study investigators recorded HR and blood pressure data during DSE testing and were blind to the genotype of each patient at the time of data recording.
Genotyping methods
Following DSE, genomic DNA was isolated from whole blood or mouthwash samples using a commercially available kit (Puregene; Gentra Systems, Minneapolis, MN, USA). Genotypes were determined by one of three methods: Orchid BioSciences Inc.'s (Princeton, NJ, USA), proprietary single primer extension technology (SNP-IT), pyrosequencing or polymerase chain reaction-restriction fragment length polymorphism analysis (PCR-RFLP). Single primer extension 22 16 and b 2 -AR codon 27, respectively. PCR-RFLP for b 1 -AR codons 49 and 389 was conducted according to previously described methods using the Sau96I and BstNI restriction enzymes, respectively. 23 PCR-RFLP for b 2 -AR codons 16 and 27 was conducted according to previously described methods, using the NcoI and BbVI restriction enzymes, respectively. 24 The RFLP protocol for b 2 -AR codons 16 and 27 was modified to consist of 20 ml reactions containing 5 ml of PCR product, 5 U of NcoI (for b 2 -AR codon 16) or 3 U of BbVI (for b 2 -AR codon 27), digested for 2 h at 37 1C. Genotypes were scored by two independent investigators.
Statistical analysis
Based on allele frequencies, it was expected that the number of b 1 -AR Gly49 homozygotes and Gly389 homozygotes would be low. As such, it was planned a priori that Gly homozygotes would be combined with heterozygotes for each b 1 -AR polymorphism. For example, b 1 -AR Gly389 carriers were those with either the Arg389Gly genotype or the Gly389Gly genotype. Genotype frequencies were determined by allele counting, and Hardy-Weinberg equilibrium was tested using w 2 -analysis. Categorical baseline characteristics were compared between groups using w 2 -tests. Baseline characteristics were compared using Student's unpaired t-tests for the b 1 -AR polymorphism data, and one-way analysis of variance (ANOVA) for the b 2 -AR polymorphism data. Following ANOVA, post hoc analysis was performed using the least significant differences t-test. Dobutamineinduced changes in HR, SBP and DBP were analyzed by the Mixed Procedures (PROC MIXED) method in SAS to account for the repeated measures design of the study. Race/ethnicity (Caucasian, Black, Hispanic, other) was included as a covariate in PROC MIXED analysis. The PROC MIXED covariance structures used were compound symmetry, autoregressive order 1 and unstructured. Two model-fit criteria, Akaike's Information Criteria and Schwarz' Bayesian Criterion, were used to determine which of the three covariance structure models to select for final inference.
Due to known racial differences in b 1 -and b 2 -AR polymorphism allele frequencies, resting hemodynamic data, and dobutamine-induced changes in HR, SBP and DBP were also analyzed in the Caucasian patients alone. All data were analyzed using a two-sided significance level of 0.05. Data were analyzed using SAS 8.2 (SAS Institute Inc., Cary, NC, USA) and SPSS 14.0 for Windows (SPSS Inc., Chicago, IL, USA).
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